Drug Trial Radar · NCT05974345
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
204,691
Actual
Start
Nov 3, 2023
Primary completion
Dec 15, 2023
Study completion Dec 15, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 3, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease (ASCVD) and elevated LDL-C.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodiumDrug
Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
PlaceboDrug
Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
EzetimibeDrug
Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
EvolocumabDrug
Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the first occurrence between trial start and end of follow-up of any component of 3P-MACE (composite of CV death, non-fatal MI or non-fatal ischemic stroke)Time frame: 5 years of follow-up
- Time to the first occurrence between trial start and end of follow-up of CV deathTime frame: 5 years of follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Rueil-Malmaison, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.